Primary and secondary long-term prophylaxis of thromboembolism in outpatients with the low-molecular-weight heparin Kabi 2165

Haemostasis. 1988:18 Suppl 3:78-81. doi: 10.1159/000215872.

Abstract

Bleeding episodes and other side effects may complicate the treatment with oral anticoagulants. We report on the results of 66 patients who were treated with a low molecular weight heparin fraction for up to 19 months. The data of the study demonstrate the effective long-term anticoagulation with low-molecular-weight heparin and the reduced incidence of hemorrhages compared with conventional anticoagulants. Thus, low-molecular-weight heparin may be effectively and safely used for long-term anticoagulation in patients with bleeding problems on conventional anticoagulants.

Publication types

  • Clinical Trial

MeSH terms

  • Clinical Trials as Topic
  • Factor Xa
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Serine Proteinase Inhibitors
  • Thromboembolism / prevention & control*

Substances

  • Heparin, Low-Molecular-Weight
  • Serine Proteinase Inhibitors
  • Factor Xa